A prospective phase Ⅱstudy of Gabapentin combined with Oxycontin in the treatment of pain in radiation oral mucositis
XIA Xiao-long1 ZHANG Wen-ping1 HU Jian-bing2 SHU yun1 WANG Hong-yun1 WANG Xu3 ZOU Cai-liang1 GAN Xiao-ling
1. The First Department of Abdominal Tumor, the Third People′s Hospital of Jiujiang City, Jiangxi Province, Jiujiang 332000, China;
2. Department of Internal Medicine, De′an County People′s Hospital, Jiangxi Province, De′an 330400,China;
3. Department of Imaging, the Third People′s Hospital of Jiujiang City, Jiangxi Province, Jiujiang 332000, China
Abstract：Objective To study the effect of Gabapentin combined with Oxycontin in the treatment of pain in radiation oral mucositis. Methods From May 2019 to September 2020, 58 patients with radiation oral mucositis who were treated in the Third People′s Hospital of Jiujiang City were selected as the research subjects. According to the random number table method, they were divided into control group (29 cases) and treatment group (29 cases). Patients in the control group were treated with Oxycontin, and patients in the treatment group were treated with Gabapentin combined with Oxycontin. Both groups were treated for eight weeks. The pain scores of numeric rating scale (NRS) scores of the two groups were compared before treatment and at 2, 4, 6 and 8 weeks after treatment. The proportions of grade 1-2 and grade 3-4 in oral mucosa radiation injury grading were compared between the two groups after 2 and 8 weeks of treatment. The quality of life 1 week before radiotherapy and the end day of radiotherapy and the incidence of adverse reactions during treatment were compared between the two groups. The total cost of analgesics after treatment was compared between the two groups. Results There was no statistically significant difference in NRS score of patients between the two groups before treatment (P>0.05). The NRS scores of the two groups at 2, 4, 6 and 8 weeks of treatment were lower than those before treatment, with statistically significant differences (P<0.05). The NRS scores of the two groups at 4, 6 and 8 weeks of treatment were lower than those at 2 weeks of treatment, with statistically significant differences (P<0.05). The NRS score of the two groups at 6 and 8 weeks of treatment were lower than those at 4 weeks of treatment, with statistically significant differences (P<0.05). The NRS score of the two groups at the 8 weeks of treatment was lower than that at the 6th week of treatment, the difference was statistically significant (P<0.05). The NRS scores in the treatment group were lower than those in the control group at 2, 4, 6 and 8 weeks of treatment, with statistically significant differences (P<0.05). The proportions of oral mucosal radiation injury grade 1-2 in treatment group at the 2 and 8 weeks of treatment were higher than those in control group, and the differences were statistically significant (P<0.05). The proportions of oral mucosal radiation injury grade 3-4 in the treatment group at 2 and 8 weeks of treatment were lower than those in the control group, and the differences were statistically significant (P<0.05). There was no significant difference in the European Organization for Research and Treatment of Cancer head and neck cancer quality questionnaire (EORTC QLQ-H&N35) score between the two groups one week before radiotherapy (P>0.05). The EORTC QLQ-H&N35 scores at the end of radiotherapy in the two groups were lower than those one week before radiotherapy, the differences were statistically significant (P<0.05). The EORTC QLQ-H&N35 score of the treatment group was lower than that of the control group at the end of radiotherapy, the difference was statistically significant (P<0.05). The total incidence of adverse reactions in the treatment group was lower than that in the control group, and the difference was statistically significant (P<0.05). The total cost of analgesics in the treatment group was less than that in the control group after treatment, and the difference was statistically significant (P<0.05). Conclusion Gabapentin combined with Oxycontin can effectively reduce the pain degree and oral mucosal reactions of patients with radiation oral mucositis, reduce the occurrence of adverse reactions, improve the quality of life, and reduce the economic burden of drugs.
夏小龙； 张文平； 胡建兵；疏云； 王洪云；汪徐； 邹彩亮；甘小玲. 加巴喷丁联合奥施康定治疗放射性口腔黏膜炎疼痛的前瞻性Ⅱ期研究[J]. 中国当代医药, 2021, 28(21): 19-22转28.
XIA Xiao-long；ZHANG Wen-ping；HU Jian-bing； SHU yun； WANG Hong-yun； WANG Xu； ZOU Cai-liang；GAN Xiao-ling. A prospective phase Ⅱstudy of Gabapentin combined with Oxycontin in the treatment of pain in radiation oral mucositis. 中国当代医药, 2021, 28(21): 19-22转28.
京公网安备 11010502046607号